Advertisement

CNS Drugs

, Volume 22, Issue 2, pp 87–97 | Cite as

Treatment of Cognitive Impairment in Multiple Sclerosis

Is the Use of Acetylcholinesterase Inhibitors a Viable Option?
  • Christopher Christodoulou
  • William S. MacAllister
  • Nancy A. McLinskey
  • Lauren B. Krupp
Current Opinion

Abstract

Approximately half of all patients with multiple sclerosis (MS) experience cognitive impairment, most commonly with regard to new learning and memory. Cognitive dysfunction is a leading cause of disability in MS and it can have profound social and economic consequences for patients and their families.

Research on treatment for cognitive impairment in MS is still in the early stages, as it is for most neurological conditions. The available disease-modifying therapies in MS may provide some modest benefit to cognition, but patients with MS clearly need better treatment for cognitive dysfunction. A number of studies have assessed symptomatic treatments of cognition in MS, and the results of these small, underpowered studies have been mixed. Regardless, acetylcholinesterase inhibitors (AChEIs) have been the most promising class of medications tested in MS to date. Seven of eight studies on AChEIs have shown positive results, although it is difficult to assess their adequacy. Only three of the AChEI studies have been published in peer reviewed journals, with the rest appearing only as abstracts. The earliest AChEI studies in MS examined physostigmine, but the short half-life and prominent adverse effects of this medication may have limited its use compared with other AChEIs. All of the more recent AChEI studies have used donepezil, which, from the limited data available to date, appears to have been relatively well tolerated among MS patients. The largest randomized controlled trial of donepezil included 69 subjects and found that donepezil improved verbal learning and memory compared with placebo during neuropsychological testing. That study also found that patients receiving donepezil were more likely to report memory improvement than those receiving placebo, and the study clinician also noted a cognitive benefit among those on donepezil as opposed to placebo.

There are still many unanswered questions regarding the use of AChEIs in MS, including the effects of their long-term use in a chronic disease such as MS. On the whole, to date the research on AChEIs in MS must be considered preliminary, and it is premature to recommend the clinical use of this class of medications at the present time.

Keywords

Multiple Sclerosis Cognitive Impairment Multiple Sclerosis Patient Expand Disability Status Scale Vascular Dementia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Supported by the National Institutes of Health (grant no. HD38107-01), the National Institutes for Disability and Rehabilitation Research (grant no. H133G990058), the National Multiple Sclerosis Society (grant no. RG3042-A-2) and the National Center for Research Resources (grant no. M01-RR10710-02). The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Kurtzke JF, Page WF, Murphy FM, et al. Epidemiology of multiple sclerosis in United States veterans: 4. Age at onset. Neuroepidemiology 1992; 11: 226–35PubMedCrossRefGoogle Scholar
  2. 2.
    Peyser JM, Edwards KR, Poser CM, et al. Cognitive function in patients with multiple sclerosis. Arch Neurol 1980; 37(9): 577–9PubMedCrossRefGoogle Scholar
  3. 3.
    Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology 1991; 41(5): 685–91Google Scholar
  4. 4.
    Thornton AE, Raz N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychology 1997; 11(3): 357–66PubMedCrossRefGoogle Scholar
  5. 5.
    Deluca J, Gaudino EA, Diamond BJ, et al. Acquisition and storage deficits in multiple sclerosis. J Clin Exp Neuropsychol 1998; 20(3): 376–90PubMedCrossRefGoogle Scholar
  6. 6.
    Beatty WW, Wilbanks SL, Blanco CR, et al. Memory disturbance in multiple sclerosis: reconsideration of patterns of performance on the selective reminding test. J Clin Exp Neuropsychol 1996; 18(1): 56–62PubMedCrossRefGoogle Scholar
  7. 7.
    Ruchkin DS, Grafman J, Krauss GL, et al. Event-related brain potential evidence for a verbal working-memory deficit in multiple-sclerosis. Brain 1994; 117: 289–305PubMedCrossRefGoogle Scholar
  8. 8.
    Diamond BJ, Deluca J, Kim HJ, et al. The question of disproportionate impairments in visual and auditory information processing in multiple sclerosis. J Clin Exp Neuropsychol 1997; 19(1): 34–42PubMedCrossRefGoogle Scholar
  9. 9.
    D’;Esposito M, Onishi K, Thompson H, et al. Working memory impairments in multiple sclerosis: evidence from a dual-task paradigm. Neuropsychology 1996; 10(1): 51–6CrossRefGoogle Scholar
  10. 10.
    Beatty WW, Goodkin DE, Beatty PA, et al. Frontal-lobe dysfunction and memory impairment in patients with chronic progressive multiple-sclerosis. Brain Cogn 1989; 11(1): 73–86PubMedCrossRefGoogle Scholar
  11. 11.
    Arnett PA, Rao SM, Grafman J, et al. Executive functions in multiple sclerosis: an analysis of temporal ordering, semantic encoding, and planning abilities. Neuropsychology 1997; 11(4): 535–44PubMedCrossRefGoogle Scholar
  12. 12.
    Foong J, Rozewicz L, Quaghebeur G, et al. Executive function in multiple sclerosis: the role of frontal lobe pathology. Brain 1997; 120(Pt 1): 15–26PubMedCrossRefGoogle Scholar
  13. 13.
    van den Burg W, van Zomeren AH, Minderhoud JM, et al. Cognitive impairment in patients with multiple sclerosis and mild physical disability. Arch Neurol 1987; 44: 494–501PubMedCrossRefGoogle Scholar
  14. 14.
    Minden SL, Moes EJ, Orav J, et al. Memory impairment in multiple-sclerosis. J Clin Exp Neuropsychol 1990; 12(4): 566–86PubMedCrossRefGoogle Scholar
  15. 15.
    Huijbregts SCJ, Kalkers NF, de Sonneville LMJ, et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 2004; 63(2): 335–9PubMedCrossRefGoogle Scholar
  16. 16.
    Denney DR, Sworowski LA, Lynch SG. Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol 2005; 20(8): 967–81PubMedCrossRefGoogle Scholar
  17. 17.
    Huijbregts SCJ, Kalkers NF, de Sonneville LMJ, et al. Cognitive impairment and decline in different MS subtypes. J Neurol Sci 2006; 245(1–2): 187–94PubMedCrossRefGoogle Scholar
  18. 18.
    Wachowius U, Talley M, Silver N, et al. Cognitive impairment in primary and secondary progressive multiple sclerosis. J Clin Exp Neuropsychol 2005; 27(1): 65–77PubMedCrossRefGoogle Scholar
  19. 19.
    Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74(4): 443–6PubMedCrossRefGoogle Scholar
  20. 20.
    Amato MP, Zipoli V, Goretti B, et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 2006; 253(8): 1054–9PubMedCrossRefGoogle Scholar
  21. 21.
    Amato MP, Ponziani G, Pracucci G, et al. Cognitive impairment in early-onset MS: a reappraisal after a 10-year follow-up [abstract]. Neurology 1999; 52(6): A499Google Scholar
  22. 22.
    Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis: a controlled 3-year follow-up. Brain 1997; 120 (Pt 2): 289–97PubMedCrossRefGoogle Scholar
  23. 23.
    Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple sclerosis: II. Impact on employment and social functioning. Neurology 1991; 41(5): 692–6Google Scholar
  24. 24.
    Beatty WW. Cognitive and emotional disturbances in multiple sclerosis. Neurol Clin 1993; 11(1): 189–204PubMedGoogle Scholar
  25. 25.
    Beatty WW, Blanco CR, Wilbanks SL, et al. Demographic, clinical, and cognitive characteristics of multiple sclerosis patients who continue to work. J Neurol Rehabil 1995; 9: 167–73Google Scholar
  26. 26.
    Wild KV, Lezak M, Whitman RH, et al. Psychosocial impact of cognitive impairment in the multiple sclerosis patient [abstract]. J Clin Exp Neuropsychol 1991; 13: 74Google Scholar
  27. 27.
    Schultheis MT, Garay E, Millis SR, et al. Motor vehicle crashes and violations among drivers with multiple sclerosis. Arch Phys Med Rehabil 2002; 83(8): 1175–8PubMedCrossRefGoogle Scholar
  28. 28.
    Schultheis MT, Garay E, Deluca J. The influence of cognitive impairment on driving performance in multiple sclerosis. Neurology 2001; 56(8): 1089–94PubMedCrossRefGoogle Scholar
  29. 29.
    Shawaryn MA, Schultheis MT, Garay E, et al. Assessing functional status: exploring the relationship between the multiple sclerosis functional composite and driving. Arch Phys Med Rehabil 2002; 83(8): 1123–9PubMedCrossRefGoogle Scholar
  30. 30.
    Fischer JS. Assessment of neuropsychological function. In: Rudick RA, Goodkin DE, editors. Multiple sclerosis therapeutics. London: Martin Dunitz, 1999: 31–47Google Scholar
  31. 31.
    Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11(2): 131–45PubMedGoogle Scholar
  32. 32.
    Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donezepil in patients with Alzheimer’;s disease. Neurology 1998; 50: 136–45PubMedCrossRefGoogle Scholar
  33. 33.
    Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’;s disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10(3): 237–44PubMedCrossRefGoogle Scholar
  34. 34.
    Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer’;s disease. Int J Neuropsychopharmacol 2004; 7(3): 351–69PubMedCrossRefGoogle Scholar
  35. 35.
    Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’;s disease. Cochrane Database Syst Rev 2003; (3): CD001190Google Scholar
  36. 36.
    Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57(3): 489–95PubMedCrossRefGoogle Scholar
  37. 37.
    Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’;s disease. Am J Psychiatry 1984; 141(11): 1356–64PubMedGoogle Scholar
  38. 38.
    Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer’;s Disease Cooperative Study-clinical global impression of change. The Alzheimer’;s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11Suppl. 2: S22–32PubMedCrossRefGoogle Scholar
  39. 39.
    Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates, 1988Google Scholar
  40. 40.
    NMSS Cognition and MS Task Force. Assessment and management of cognitive impairment in multiple sclerosis. Expert opinion paper from the Medical Advisory Board of the National Multiple Sclerosis Society, 2006 [online]. Available from URL: http://www.nationalmssociety.org/site/PageServer?pagename=HOM_PRO_expert_opinion_papers [Accessed 2007 Dec 19]
  41. 41.
    Chiaravalloti ND, Deluca J. Self-generation as a means of maximizing learning in multiple sclerosis: an application of the generation effect. Arch Phys Med Rehabil 2002; 83(8): 1070–9PubMedCrossRefGoogle Scholar
  42. 42.
    Chiaravalloti ND, Deluca J, Moore NB, et al. Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Multiple Sclerosis 2005; 11(1): 58–68PubMedCrossRefGoogle Scholar
  43. 43.
    Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48(6): 885–92Google Scholar
  44. 44.
    Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996; 47(6): 1463–8PubMedCrossRefGoogle Scholar
  45. 45.
    Weinstein A, Schwid SI, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999; 56(3): 319–24PubMedCrossRefGoogle Scholar
  46. 46.
    Boringa JB, Lazeron RH, Reuling IE, et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler 2001; 7(4): 263–7PubMedGoogle Scholar
  47. 47.
    Greene YM, Tariot PN, Wishart H, et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000; 20(3): 350–6PubMedCrossRefGoogle Scholar
  48. 48.
    Jonsson A, Korfitzen EM, Heltberg A, et al. Effects of neuropsychological treatment in patients with multiple sclerosis. Acta Neurol Scand 1993; 88(6): 394–400PubMedCrossRefGoogle Scholar
  49. 49.
    Leo GJ, Rao SM. Effects of intravenous physostigmine and lecithin on memory in multiple sclerosis: report of a pilot study. J Neurol Rehabil 1988; 2: 123–9Google Scholar
  50. 50.
    Plohmann AM, Kappos L, Ammann W, et al. Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64(4): 455–62PubMedCrossRefGoogle Scholar
  51. 51.
    Krupp LB, Christodoulou C, Melville P, et al. Interventions to improve memory in MS. The aricept in MS study (AIMS): 24 week data. Neurology 2003; 60Suppl. 1: A477Google Scholar
  52. 52.
    Bever Jr CT, Anderson PA, Leslie J, et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996; 47(6): 1457–62PubMedCrossRefGoogle Scholar
  53. 53.
    Geisler MW, Sliwinski M, Coyle PK, et al. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996; 53(2): 185–8PubMedCrossRefGoogle Scholar
  54. 54.
    Oliveri RL, Valentino P, Russo C, et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998; 50(6): 1833–6PubMedCrossRefGoogle Scholar
  55. 55.
    Rodgers D, Khoo K, MacEachen M, et al. Cognitive therapy for multiple sclerosis: a preliminary study. Altern Ther Health Med 1996; 2(5): 70–4PubMedGoogle Scholar
  56. 56.
    Smits RC, Emmen HH, Bertelsmann FW, et al. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 1994; 44(9): 1701–5PubMedCrossRefGoogle Scholar
  57. 57.
    Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple-sclerosis. Arch Neurol 1989; 46(6): 676–80PubMedCrossRefGoogle Scholar
  58. 58.
    Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001; 7(6): 354–8PubMedGoogle Scholar
  59. 59.
    Unverzagt FW, Rao SM, Antuono PG. Oral physostigmine in the treatment of memory loss in multiple sclerosis (MS) [abstract]. J Clin Exp Neuropsychol 1991; 13(1): 74Google Scholar
  60. 60.
    Krupp LB, Elkins LE, Scheffer S, et al. Donepezil for the treatment of memory impairments in multiple sclerosis [abstract]. Neurology 1999; 52Suppl. 2: A137Google Scholar
  61. 61.
    Rorie KD, Stump DA, Jeffery DR. Effects of donepezil on cognitive function in patients with multiple sclerosis [abstract]. Neurology 2001; 56Suppl. 3: A99Google Scholar
  62. 62.
    Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63: 1579–85PubMedCrossRefGoogle Scholar
  63. 63.
    Decoo D. Effects of donepezil in multiple sclerosis: a single-centre trial [abstract]. Multiple Sclerosis 2004; 10(7032): S150Google Scholar
  64. 64.
    Boscà L, Andreu M, Bueno A, et al. Donepezil and cognitive impairment in multiple sclerosis: a double-blind pilot study [abstract]. Multiple Sclerosis 2004; 10 (7032): S150Google Scholar
  65. 65.
    Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974; 24(11): 1019–25PubMedCrossRefGoogle Scholar
  66. 66.
    Coelho F, Birks J. Physostigmine for Alzheimer’;s disease. Cochrane Database Syst Rev 2001; (2): CD001499Google Scholar
  67. 67.
    Rao SM, Cognitive Function Study Group of the National Multiple Sclerosis Society. A manual for the brief, repeatable battery of neuropsychological tests in multiple sclerosis. Milwaukee (WI): Section of Neuropsychology, Medical College of Wisconsin, 1990Google Scholar
  68. 68.
    Harris G. Study of Alzheimer’;s drug revives questions on risk. New York Times, 2006 Mar 17Google Scholar
  69. 69.
    Levin HS, Peters BH, Kalisky Z, et al. Effects of oral physostigmine and lecithin onmemory and attention in closed head-injured patients. Cent Nerv Syst Trauma 1986; 3(4): 333–42PubMedGoogle Scholar
  70. 70.
    Taverni JP, Seliger G, Lichtman SW. Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj 1998; 12(1): 77–80PubMedCrossRefGoogle Scholar
  71. 71.
    Whitlock Jr JA. Brain injury, cognitive impairment, and donepezil. J Head Trauma Rehabil 1999; 14(4): 424–7PubMedCrossRefGoogle Scholar
  72. 72.
    Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson’;s disease dementia. Cochrane Database Syst Rev 2006; (1): CD004747Google Scholar
  73. 73.
    Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson’;s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72(6): 708–12PubMedCrossRefGoogle Scholar
  74. 74.
    Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’;s disease. N Engl J Med 2004; 351(24): 2509–18PubMedCrossRefGoogle Scholar
  75. 75.
    Fernandez HH, Friedman JH, Grace J, et al. Donepezil for Huntington’;s disease. Mov Disord 2000; 15(1): 173–6PubMedCrossRefGoogle Scholar
  76. 76.
    Kishnani PS, Sullivan JA, Walter BK, et al. Cholinergic therapy for Down’;s syndrome. Lancet 1999; 353(9158): 1064–5PubMedCrossRefGoogle Scholar
  77. 77.
    Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer’;s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359(9314): 1283–90PubMedCrossRefGoogle Scholar
  78. 78.
    Roman GC, Wilkinson DG, Doody RS, et al. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005; 20(6): 338–44PubMedCrossRefGoogle Scholar
  79. 79.
    Furey ML, Pietrini P, Haxby JV, et al. Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memory. Proc Natl Acad Sci U S A 1997; 94(12): 6512–6PubMedCrossRefGoogle Scholar
  80. 80.
    Furey ML, Pietrini P, Alexander GE, et al. Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans. Brain Res Bull 2000; 51(3): 213–8PubMedCrossRefGoogle Scholar
  81. 81.
    Furey ML, Pietrini P, Haxby JV. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 2000; 290(5500): 2315–9PubMedCrossRefGoogle Scholar
  82. 82.
    Hutchison CW, Nathan PJ, Mrazek L, et al. Cholinergic modulation of speed of early information processing: the effect of donepezil on inspection time. Psychopharmacology (Berl) 2001; 155(4): 440–2CrossRefGoogle Scholar
  83. 83.
    Yesavage JA, Mumenthaler MS, Taylor JL, et al. Donepezil and flight simulator performance: effects on retention of complex skills. Neurology 2002; 59(1): 123–5PubMedCrossRefGoogle Scholar
  84. 84.
    Mumenthaler MS, Yesavage JA, Taylor JL, et al. Psychoactive drugs and pilot performance: a comparison of nicotine, donepezil, and alcohol effects. Neuropsychopharmacology 2003; 28(7): 1366–73PubMedCrossRefGoogle Scholar
  85. 85.
    Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158(9): 1021–31Google Scholar
  86. 86.
    Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’;s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7(6): 293–303Google Scholar
  87. 87.
    Ruberg M, Villageois A, Bonnet AM, et al. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. J Neurol Neurosurg Psychiatry 1987; 50(5): 538–43PubMedCrossRefGoogle Scholar
  88. 88.
    D’;Intino G, Paradisi M, Fernandez M, et al. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci U S A 2005; 102(8): 3070–5CrossRefGoogle Scholar
  89. 89.
    Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338(5): 278–85PubMedCrossRefGoogle Scholar
  90. 90.
    Chamelian L, Bocti C, Gao FQ, et al. Detecting cognitive dysfunction in multiple sclerosis with a magnetic resonance imaging rating scale: a pilot study. CNS Spectr 2005; 10(5): 394–401PubMedGoogle Scholar
  91. 91.
    Blin J, Ray CA, Piercey MF, et al. Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography. Brain Res 1994; 635(1–2): 196–202PubMedCrossRefGoogle Scholar
  92. 92.
    Hakansson L. Mechanism of action of cholinesterase inhibitors in Alzheimer’;s disease. Acta Neurol Scand Suppl 1993; 149: 7–9PubMedCrossRefGoogle Scholar
  93. 93.
    Nordberg A, Lilja A, Lundqvist H, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992; 13(6): 747–58PubMedCrossRefGoogle Scholar
  94. 94.
    Robbins TW, Mehta MA, Sahakian BJ. Neuroscience: boosting working memory. Science 2000; 290(5500): 2275–6PubMedCrossRefGoogle Scholar
  95. 95.
    Parry AMM, Scott RB, Palace J, et al. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 2003; 126: 2750–60PubMedCrossRefGoogle Scholar
  96. 96.
    Saykin AJ, Wishart HA, Rabin LA, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 2004; 127 (Pt 7): 1574–83PubMedCrossRefGoogle Scholar
  97. 97.
    Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003; 349(23): 2274–5PubMedCrossRefGoogle Scholar
  98. 98.
    Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 2003; 165(3): 260–9PubMedGoogle Scholar
  99. 99.
    Porrino LJ, Daunais JB, Rogers GA, et al. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. Plos Biology 2005; 3(9): 1639–52CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Christopher Christodoulou
    • 1
  • William S. MacAllister
    • 2
  • Nancy A. McLinskey
    • 1
  • Lauren B. Krupp
    • 1
  1. 1.Department of NeurologyState University of New York at Stony BrookStony BrookUSA
  2. 2.Department of Neurology, Comprehensive Epilepsy CenterNew York UniversityNew YorkUSA

Personalised recommendations